Izabella Skulimowska

Izabella Skulimowska

Auto-generated profile, based on publicly available information

Izabella Skulimowska

Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
ISIzabella Skulimowska
Izabella Skulimowska
JSJustyna Sośniak
Justyna Sośniak
MGMonika Gonka
Monika Gonka
ASAgata Szade
Agata Szade
AJAlicja Józkowicz
Alicja Józkowicz
KSKrzysztof Szade
Krzysztof Szade
Hematopoietic stem cells (HSCs) give rise to all types of blood cells and self‐renew their own population. The regeneration potential of HSCs has already been successfully translated into clinical applications. However, recent studies on the biology of HSCs may further extend their clinical use in future. The roles of HSCs in native hematopoiesis and in transplantation settings may differ. Furthermore, the heterogenic pool of HSCs dynamically changes during aging. These changes also involve the complex interactions of HSCs with the bone marrow niche. Here, we review the opportunities and challenges of these findings to improve the clinical use of HSCs. We describe new methods of HSCs mobilization and conditioning for the transplantation of HSCs. Finally, we highlight the research findings that may lead to overcoming the current limitations of HSC transplantation and broaden the patient group that can benefit from the clinical potential of HSCs.

29 December 2019 in EMBO Reports
Verified
Journal Article
Open access
PDF file
KSKrzysztof Szade
Krzysztof Szade
MZMonika Zukowska
Monika Zukowska
ASAgata Szade
Agata Szade
WNWitold Nowak
Witold Nowak
ISIzabella Skulimowska
Izabella Skulimowska
AJAlicja Józkowicz
Alicja Józkowicz
While intrinsic changes in aging hematopoietic stem cells (HSCs) are well characterized, it remains unclear how extrinsic factors affect HSC aging. Here, we demonstrate that cells in the niche—endothelial cells (ECs) and CXCL12‐abundant reticular cells (CARs)—highly express the heme‐degrading enzyme, heme oxygenase 1 (HO‐1), but then decrease its expression with age. HO‐1‐deficient animals (HO‐1 −/− ) have altered numbers of ECs and CARs that produce less hematopoietic factors. HSCs co‐cultured in vitro with HO‐1 −/− mesenchymal stromal cells expand, but have altered kinetic of growth and differentiation of derived colonies. HSCs from young HO‐1 −/− animals have reduced quiescence and regenerative potential. Young HO‐1 −/− HSCs exhibit features of premature exhaustion on the transcriptional and functional level. HO‐1 +/+ HSCs transplanted into HO‐1 −/− recipients exhaust their regenerative potential early and do not reconstitute secondary recipients. In turn, transplantation of HO‐1 −/− HSCs to the HO‐1 +/+ recipients recovers the regenerative potential of HO‐1 −/− HSCs and reverses their transcriptional alterations. Thus, HSC‐extrinsic activity of HO‐1 prevents HSCs from premature exhaustion and may restore the function of aged HSCs.

9 July 2025 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
ABAleksandra Bednarz
Aleksandra Bednarz
PKPaweł Kożuch
Paweł Kożuch
KKKacper Kowalski
Kacper Kowalski
ISIzabella Skulimowska
Izabella Skulimowska
NKNeli Kachamakova-Trojanowska
Neli Kachamakova-Trojanowska
ASAgata Szade
Agata Szade
Background: Recombinant granulocyte colony-stimulating factor (G-CSF) is the most commonly used agent for treating neutropenia and mobilizing hematopoietic stem cells (HSCs) for transplantation. However, some patients do not respond effectively to the currently used mobilization protocols. To address this, new therapeutic approaches are needed. A potential strategy is pharmacological induction of endogenous mobilizing factors via cobalt protoporphyrin IX (CoPP). CoPP mobilizes HSCs and granulocytes by increasing endogenous G-CSF, though optimal dosing and potential side effects remain unclear. Our study aimed to optimize CoPP dosing and timing, and assess its safety in mobilizing cells from bone marrow to blood. Methods: Mice were treated with different doses of CoPP, and blood cell counts, cytokine concentrations, and organ damage markers were evaluated at various time points after injection. Results: Our results show that CoPP exerts a dose-dependent mobilizing effect, with the highest G-CSF levels and number of mobilized leukocytes observed in mice treated with 10 mg/kg of CoPP. While there were no severe adverse effects, there were mild fluctuations in markers of organ function, including a reduction in blood urea nitrogen (BUN) and glucose levels during the five days of administration. Additionally, although most parameters normalized within 30 days, the decrease in BUN persisted. Mice experienced short-term weight loss following CoPP administration, but they regained their initial weight within two weeks. Conclusions: This study demonstrates that CoPP mobilizes cells from the bone marrow to the blood in a dose-dependent manner, with mild side effects, including temporary changes in biochemical markers and a sustained reduction in BUN levels.

25 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAleksandra Bednarz
Aleksandra Bednarz
PKPaweł Kozuch
Paweł Kozuch
KKKacper Kowalski
Kacper Kowalski
ISIzabella Skulimowska
Izabella Skulimowska
NKNeli Kachamakova-Trojanowska
Neli Kachamakova-Trojanowska
ASAgata Szade
Agata Szade
Recombinant granulocyte colony-stimulating factor (G-CSF) is the most commonly used agent for treating neutropenia and mobilizing hematopoietic stem cells (HSCs) for transplantation. However, some patients do not respond effectively to existing mobilization protocols. To address this, the development of new therapeutic approaches is necessary. One potential strategy is the pharmacological induction of endogenous mobilizing factors, which can be achieved through the administration of cobalt protoporphyrin IX (CoPP). CoPP induces mobilization of HSCs and granulocytes by increasing endogenous G-CSF production, though the optimal dosing and potential side effects remain unclear. The aim of our study was to optimize the dose and timing of CoPP administration and evaluate its safety in mobilizing cells from the bone marrow to the blood. Our results show that CoPP exerts a dose-dependent mobilizing effect, with the highest G-CSF levels and number of mobilized leukocytes observed in mice treated with 10 mg/kg of CoPP. While there were no severe adverse effects, there were mild fluctuations in markers of liver and kidney function, including a slight reduction in urea nitrogen (BUN) and glucose levels during the five days of administration. Additionally, although most parameters normalized within 30 days after treatment, the decrease in BUN persisted. Mice experienced short-term weight loss following CoPP administration, but they regained their initial weight within two weeks. By day 30, leukocyte counts, hematopoietic stem and progenitor cells (HSPCs) in bone marrow, and G-CSF concentration in the blood had returned to baseline. This study demonstrates that CoPP mobilizes cells from the bone marrow to the blood in a dose-dependent manner, with mild side effects, including temporary changes in biochemical markers and a sustained reduction in BUN levels.